Clinical Trials for Mesothelioma Patients: Bortezomib Study Criteria

Read the study criteria about a current clinical trial being conducted to study the effects of Bortezomib for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. At this time, the clinical trials are not being conducted in the United States.

Criteria:
Inclusion criteria:
• Histologically confirmed malignant pleural mesothelioma
• Meets 1 of the following criteria for first-line or second-line chemotherapy:
o Patients in the first-line setting must be unsuitable for, cannot access locally, or refuse combination chemotherapy
o Patients in the second-line setting must be unsuitable for, cannot access locally, or refuse cytotoxic chemotherapy after failure of a first-line regimen
Second-line patients may not have received more than 1 prior line of antineoplastic treatment for this cancer
• Pleural effusions should be drained before treatment whenever possible
o Talc or tetracycline pleurodesis may be used per standard practice for uncontrollable pleural effusions (recurrent despite regular drainage)
Exclusion criteria:
• Symptomatic or known brain or leptomeningeal metastases

Courtesy of ClinicalTrials.gov,

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney